首页 | 本学科首页   官方微博 | 高级检索  
     


Vildagliptin in patients with type 2 diabetes mellitus and renal impairment
Affiliation:1. Department of Medicine, Division of Cardiology, University of California, 333 City Tower West, Suite 400, Orange, CA 92868, United States;2. Irvine-School of Medicine, Irvine, CA, United States;3. Department of Radiology, University of Southern California, Los Angeles, CA, United States;1. Endocrinology Unit-Hospital de Clínicas de Porto Alegre, Postgraduate Fellowship Program in Endocrinology-Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil;2. Centro de Endocrinologia do Estado da Bahia (CEDEBA), Salvador, Brazil;3. Universidade do Estado da Bahia (UNEB), Salvador, Brazil;4. Pediatric Endocrinology Unit, Santa Casa de Misericórdia, São Paulo, Brazil;5. Instituto da Criança, Hospital das Clínicas, Universidade de São Paulo (USP), Brazil;6. Laboratory of Molecular and Translacional Endocrinology, Universidade Federal de São Paulo (UNIFESP), Brazil;7. Diabetes Center, Universidade Federal de São Paulo (UNIFESP), Brazil;1. Division of Endocrinology & Metabolism, Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea;2. Health Screening & Promotion Center, Asan Medical Center, Seoul, South Korea;1. Istanbul University, Istanbul Faculty of Medicine, Department of Biochemistry, Capa, Istanbul 34093, Turkey;2. Istanbul University, Istanbul Faculty of Medicine, Department of Pathology, Capa, Istanbul 34093, Turkey
Abstract:
Keywords:Anti-hyperglycaemic agent  Dipeptidyl peptidase-4 inhibitor  Renal impairment  Type 2 diabetes mellitus  Vildagliptin
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号